Critical Reviews in Oncology Hematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

5-Lipoxygenase: its involvement in gastrointestinal malignancies
Chronic inflammation is increasingly known as one of the most critical etiological factors in gastrointestinal (GI) cancers (Lee et al., 2016; Wang and Cho, 2015). Overexpression of 5-lipoxygenase (5-LOX), 5-LOX-activating protein (FLAP), as well as other leukotriene (LT) biosynthetic enzymes have been reported in many malignant cells of the GI tract including the colon, rectum, esophagus, and pancreas (Chen et al., 2004; Li et al., 2005; Melstrom et al., 2008; Wasilewicz et al., 2010). There are several pieces of evidence suggesting that 5-LOX triggers the progression and initiation of GI malignancies (Moore and Pidgeon, ...
Source: Critical Reviews in Oncology Hematology - May 17, 2018 Category: Cancer & Oncology Authors: Neha Merchant, Lakkakula Venkata Kameswara Subrahmanya Bhaskar, Saimila Momin, Peela Sujatha, Aramati B.M. Reddy, Ganji Purnachandra Nagaraju Source Type: research

Cancer Cachexia: Diagnosis, Assessment, and Treatment
Cachexia is a multifactorial and multi-organ syndrome that is one of the main causes of morbidity and mortality in late stages of chronic conditions such as AIDS, chronic obstructive pulmonary disease (COPD), congestive heart failure, multiple sclerosis, tuberculosis, and cancer. More than 50 percent of cancer patients suffer from cachexia at death, with the distribution varying by tumor type; the incidence is highest in patients with gastric and pancreatic cancer ( ∼80%) while patients with breast cancer and leukemia demonstrate the lowest frequency (∼40%) of affliction with cachexia (Argiles et al., 2005; Muscaritoli...
Source: Critical Reviews in Oncology Hematology - May 15, 2018 Category: Cancer & Oncology Authors: Mohammadamin Sadeghi, Mahsa Keshavarz-Fathi, Vickie Baracos, Jann Arends, Maryam Mahmoudi, Nima Rezaei Source Type: research

Surgical treatment of pulmonary metastasis in colorectal cancer patients: Current practice and results
Colorectal cancer (CRC) is one of the four major cancer sites, along with breast, lung and prostate (Siegel et al., 2013; Siegel et al., 2014a). It is estimated that approximately 1  in.20 people will develop CRC over their lifetime, although this number may be decreasing, indicating progress in CRC detection or prevention (Siegel et al., 2017; Siegel et al., 2014b). Approximately 65% of all patients developing CRC will survive 5 years after the diagnosis (Siegel et al., 2013 ; Siegel et al., 2014b), but this figure varies widely with the CRC stage at detection (Siegel et al., 2013; Siegel et al., 2014a). (Source: Critic...
Source: Critical Reviews in Oncology Hematology - May 15, 2018 Category: Cancer & Oncology Authors: Matthieu Zellweger, Etienne Abdelnour-Berchtold, Thorsten Krueger, Hans-Beat Ris, Jean Yannis Perentes, Michel Gonzalez Source Type: research

The Unfolded Protein Response as a Target for Anticancer Therapeutics
The endoplasmic reticulum (ER) is an essential organelle in eukaryotic cells, responsible for protein synthesis, folding, sorting, and transportation. ER stress is initiated when the unfolded or misfolded protein load exceeds the capacity of the ER to properly fold protein. Tumor microenvironmental conditions, such as nutrient deprivation, hypoxia, and oxidative stress perturb protein folding and trigger chronic ER stress. Cancer cells can tolerate mild ER stress, however, persistent and severe ER stress kills cancer cells by inducing their autophagy, apoptosis, necroptosis, or immunogenic cell death. (Source: Critical Rev...
Source: Critical Reviews in Oncology Hematology - May 15, 2018 Category: Cancer & Oncology Authors: Mengxiong Wang, Mary E. Law, Ronald K. Castellano, Brian K. Law Source Type: research

Antinuclear antibodies and cancer: A literature review
Antinuclear antibodies (ANAs) are a spectrum of autoantibodies that react with various nuclear and cytoplasmic components of normal human cells. The development of autoantibodies is the consequence of breakdown of immunologic tolerance, but their presence is not exclusive of autoimmune conditions. They are very important serological markers for different autoimmune disease, like connective tissue diseases (CTD) —eg, systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS), scleroderma (SSc), polymyositis (PM), or mixed connective tissue disease (MCTD). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 15, 2018 Category: Cancer & Oncology Authors: Alexandru Vlagea, Sandra Falagan, Gerardo Guti érrez-Gutiérrez, Juan Moreno-Rubio, María Merino, Francisco Zambrana Tébar, Enrique Casado, María Sereno Source Type: research

A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
A considerable number of breast and ovarian carcinomas are due to underlying BRCA gene aberrations. Of these, BRCA germline mutations and BRCA promoter methylation are thought to be mutually exclusive, which could be exploited in clinical practice. However, this paradigm has not been studied extensively and systematically. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 14, 2018 Category: Cancer & Oncology Authors: Shoko Vos, Paul Joannes van Diest, Cathy Beatrice Moelans Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 12, 2018 Category: Cancer & Oncology Source Type: research

The Clinical Significance of Platelet-Derived Growth Factors (PDGFs) and their Receptors (PDGFRs) in Gastric Cancer: A Systematic Review and Meta-Analysis
This study sought to employ meta-analysis to evaluate PDGFs/PDGFRs status prognostic significance and their association with clinicopathological features of gastric cancer. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 11, 2018 Category: Cancer & Oncology Authors: Hai Qian, Kwaku Appiah-Kubi, Ying Wang, Min Wu, Yan Tao, Yan Wu, Yongchang Chen Source Type: research

Corrigendum to “Endoscopic resection with adjuvant chemo-radiotherapy for superficial esophageal squamous cell carcinoma: A critical review” [Crit. Rev. Oncol./Hematol. 124, April (2018), 61–65]
The authors regret that the authors name Jean-Louis Frossard was incorrectly spelt when the article was published. This is now correct in the article. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 4, 2018 Category: Cancer & Oncology Authors: Tsz Yeung Kam, Melpomeni Kountouri, Arnaud Roth, Jean-Louis Frossard, Olivier Huber, Stefan M önig, Thomas Zilli Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 27, 2018 Category: Cancer & Oncology Source Type: research

Paraoxonase-1 activity in patients with cancer: A systematic review and meta-analysis
The objective of the present systematic review and meta-analysis was to evaluate possible alterations in serum PON1 activity in patients with cancer. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 26, 2018 Category: Cancer & Oncology Authors: M. Arenas, E. Rodr íguez, A. Sahebkar, S. Sabater, D. Rizo, O. Pallisé, M. Hernández, F. Riu, J. Camps, J. Joven Source Type: research

“No pain, No gain” still true with immunotherapy: When the finger shows the moon, look at the moon!
For decades, standard cytotoxics have been good examples highlighting efficacy-toxicity relationships. More recently, evidences were brought by Sehouli and coworkers (Sehouli et al., 2015) analyzing retrospectively 4 controlled phase-III trials in 5114 advanced ovarian cancer patients treated with platinum and taxanes. They found that patients with grade-2 alopecia over their three first cycles exhibited significantly longer overall survival compared to patients who underwent delayed alopecia. However, the authors failed to show a clear direct link between severity of alopecia and survival, leaving open the question of an ...
Source: Critical Reviews in Oncology Hematology - April 17, 2018 Category: Cancer & Oncology Authors: G. Milano, F. Innocenti, B. Lacarelle, J. Ciccolini Source Type: research

The influence of genetic variation on late toxicities in childhood cancer survivors: A review
The variability in late toxicities among childhood cancer survivors (CCS) is only partially explained by treatment and baseline patient characteristics. Inter-individual variability in the association between treatment exposure and risk of late toxicity suggests that genetic variation possibly modifies this association. We reviewed the available literature on genetic susceptibility of late toxicity after childhood cancer treatment related to components of metabolic syndrome, bone mineral density, gonadal impairment and hearing impairment. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 12, 2018 Category: Cancer & Oncology Authors: E. Clemens, A.L.F. van der Kooi, L. Broer, E. van Dulmen-den Broeder, H. Visscher, L. Kremer, W. Tissing, J. Loonen, C.M. Ronckers, S.M.F. Pluijm, S.J.C.M.M. Neggers, O. Zolk, T. Langer, A. am Zehnhoff-Dinnesen, C.L. Wilson, M.M. Hudson, B. Carleton, J.S. Source Type: research

The influence of genetic variation on late toxicities in childhood cancer survivors: a review
The variability in late toxicities among childhood cancer survivors (CCS) is only partially explained by treatment and baseline patient characteristics. Inter-individual variability in the association between treatment exposure and risk of late toxicity suggests that genetic variation possibly modifies this association. We reviewed the available literature on genetic susceptibility of late toxicity after childhood cancer treatment related to components of metabolic syndrome, bone mineral density, gonadal impairment and hearing impairment. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - April 12, 2018 Category: Cancer & Oncology Authors: E. Clemens, A.L.F. van der Kooi, L. Broer, E. van Dulmen-den Broeder, H. Visscher, L. Kremer, W. Tissing, J. Loonen, C.M. Ronckers, S.M.F. Pluijm, S.J.C.M.M. Neggers, O. Zolk, T. Langer, A. am Zehnhoff-Dinnesen, C.L. Wilson, M.M. Hudson, B. Carleton, J.S. Source Type: research